Stock Detail
QLT INC - COMMON SHARES
Drugs
QLTI @ Yahoo Finance | QLTI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $7.02 | $7.12 | $-0.11 | -1.54% | 0.00 | $7.13 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $7.09 | $6.93 | 42,599 | 346.53M | 186,287 | -7.80 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 7.21 | 7.11 | 7.02 | 6.92 | 6.83 |
Stock Profile
QLT, Inc., a bio-pharmaceutical company, engages in the discovery, development, and commercialization of therapies in the fields of ophthalmology, dermatology, oncology, and urology primarily in North America. The company's products include Visudyne, which is used for the treatment of choroidal neovascularization; and Eligard products that are used for prostate cancer incorporate a leutinizing hormone-releasing hormone agonist, or LHRH agonist, known as leuprolide acetate with its proprietary Atrigel drug delivery system. QLT also offers generic dermatology products, including lidocaine and prilocaine cream, erythromycin and benzoyl peroxide topical gel, mometasone furoate ointment, betamethasone dipropionate cream, and fluticasone propionate cream. In addition, it provides dental products, which include Atridox and Atrisorb-D. The company has strategic alliances with Novartis Ophthalmics. QLT was formed in 1981 and is headquartered in Vancouver, Canada.